title: MicroRNA-210 overexpression predicts poorer prognosis in glioma patients.
abstract: MicroRNA-210 (miR-210) levels are elevated in many tumor types, are frequently associated with hypoxia induction, and are correlated with poor prognosis in many solid tumors. miR-210 regulates cell growth, angiogenesis, invasion, and apoptosis of many human tumors. In this study, we investigated the clinical significance of miR-210 expression in common brain tumors, or human gliomas. Glioma samples and normal brain tissues were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction to characterize the expression patterns of miR-210. The association of miR-210 expression with clinicopathological parameters and prognosis of glioma patients was statistically analyzed. Gliomas were further divided by grade: pilocytic astrocytoma (World Health Organization [WHO] grade I), diffuse astrocytomas (WHO grade II), anaplastic astrocytomas (WHO grade III), and glioblastoma (WHO grade IV). There was a significantly higher expression level of miR-210 amongst the glioma tissues as compared with normal brain tissues (p<0.001). Increased expression of miR-210 in glioma tissues was significantly associated with advanced pathological grade (p<0.001) and low Karnofsky Performance Score (p=0.014). In addition, increased miR-210 levels were also associated with poor progression-free survival (PFS) and overall survival (OS) rates when compared to the normal control (both p<0.001), as calculated by Kaplan-Meier survival and Cox regression analyses. Furthermore, subgroup analyses showed that miR-210 expression was significantly associated with poor PFS and OS of glioma patients with high pathological grades (III-IV: both p<0.001). miR-210 is highly expressed in human gliomas and confers a poor prognosis in glioma patients. These findings may bring the development of novel, tailored pharmacological therapies for glioma patients.
authors.affiliation: Department of Neurosurgery, Wuxi Second People's Hospital Affiliated to Nanjing Medical University, 68 Zhongshan Road, Wuxi City 214002, People's Republic of China.
authors.forename: Nian-Sheng
authors.initials: NS
authors.lastname: Lai
authors.affiliation: Department of Neurosurgery, First Affiliated Hospital of Nanjing Medical University, Nanjing City, People's Republic of China.
authors.forename: Qing-Sheng
authors.initials: QS
authors.lastname: Dong
authors.affiliation: Department of Neurosurgery, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing City, People's Republic of China.
authors.forename: Hao
authors.initials: H
authors.lastname: Ding
authors.affiliation: Department of Neurosurgery, Wuxi Second People's Hospital Affiliated to Nanjing Medical University, 68 Zhongshan Road, Wuxi City 214002, People's Republic of China.
authors.forename: Zeng-Li
authors.initials: ZL
authors.lastname: Miao
authors.affiliation: Department of Neurosurgery, Wuxi Second People's Hospital Affiliated to Nanjing Medical University, 68 Zhongshan Road, Wuxi City 214002, People's Republic of China. Electronic address: yuchanglin123@126.com.
authors.forename: Yu-Chang
authors.initials: YC
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D005910:Glioma / Q000175:diagnosis* / Q000378:metabolism* / Q000601:surgery; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D055815:Young Adult
chemical_list: C543800:MIRN210 microRNA, human; D035683:MicroRNAs
keywords: Glioma; MicroRNA-210; Overall survival; Progression-free survival